---
content_type: page
title: Readings
uid: 929a5c8f-c944-484a-681d-448e0140ed3b
---

\[Golan\] = Golan, David E., Armen H. Tashjian, and Ehrin J. Armstrong, eds. _Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy_. Lippincott Williams & Wilkins, 2011. ISBN: 9781608312702. \[Preview with [Google Books](http://books.google.com/books?id=WM7rvNUcrdsC&pg=PAfrontcover)\]

\[C&D\] = Klaassen, Curtis. _Casarett & Doull's Toxicology: The Basic Science of Poisons_. 8th ed. McGraw-Hill Professional, 2013. ISBN: 9780071769235.

| SES # | TOPICS | READINGS |
| --- | --- | --- |
| {{< td-colspan 4 >}}**Overview of the Drug Discovery Process; Fundamental Principles**{{< /td-colspan >}} ||||
| L1 | Introduction and Fundamentals | \[Golan\] Chapter 1 |
| L2 | Overview of Drug Development 1 | \[Golan\] Chapter 49 |
| L3 | Overview of Drug Development 2 | \[Golan\] Chapter 49 |
| R1 | Fundamentals | \[Golan\] Chapters 1 and 2 |
| L4 | Biochemistry Review Exercise | No readings for this session. |
| L5 | Uptake and Distribution |  {{< br >}}{{< br >}} \[Golan\] Chapters 2 and 3 {{< br >}}{{< br >}} \[C&D\] Chapter 5 {{< br >}}{{< br >}}  |
| L6 | Dr. Keith Hoffmaster, Novartis: Drug Transporters 1 |  {{< br >}}{{< br >}} \[Golan\] Chapter 4 {{< br >}}{{< br >}} \[C&D\] Chapter 7 {{< br >}}{{< br >}} Giacomini, Kathleen M., Shiew-Mei Huang, et al. "[Membrane Transporters in Drug Development](http://dx.doi.org/10.1038/nrd3028)." _Nature Reviews Drug Discovery_ 9, no. 3 (2010): 215–36. {{< br >}}{{< br >}} Brouwer, Kim L. R., Dietrich Keppler, et al. "[In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development.](http://www.zora.uzh.ch/93549/1/clpt201381a.pdf)" _Clinical Pharmacology & Therapeutics_ 94, no. 1 (2013): 95–112. {{< br >}}{{< br >}}  |
| L7 | Dr. Keith Hoffmaster, Novartis: Drug Transporters 2 |  {{< br >}}{{< br >}} \[Golan\] Chapter 4 {{< br >}}{{< br >}} \[C&D\] Chapter 7 {{< br >}}{{< br >}}  |
| R2 | Drug Metabolism 1 |  {{< br >}}{{< br >}} \[Golan\] Chapter 4 {{< br >}}{{< br >}}  |
| L8 | Drug Metabolism 2 |  {{< br >}}{{< br >}} \[Golan\] Chapter 4 {{< br >}}{{< br >}}  |
| L9 | Drug Toxicity 1 |  {{< br >}}{{< br >}} \[Golan\] Chapters 5 and 41 {{< br >}}{{< br >}} [![This resource may not render correctly in a screen reader.](/images/inacessible.gif)_Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation_. (PDF)](https://www.fda.gov/media/116737/download) U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). July 2009. {{< br >}}{{< br >}} Giacomini, Kathleen M., Shiew-Mei Huang, et al. "[Membrane Transporters in Drug Development](http://dx.doi.org/10.1038/nrd3028)." _Nature Reviews Drug Discovery_ 9, no. 3 (2010): 215–36. {{< br >}}{{< br >}}  |
| R3 | Lecture Review Session | No readings for this session. |
| L10 | Drug Toxicity 2 |  {{< br >}}{{< br >}} \[Golan\] Chapters 5 and 41 {{< br >}}{{< br >}}  |
| L11 | Pharmacokinetics |  {{< br >}}{{< br >}} \[Golan\] Chapters 2 and 3 {{< br >}}{{< br >}} \[C&D\] Chapter 5 {{< br >}}{{< br >}}  |
| R4 | Quiz Review | No readings for this session. |
| {{< td-colspan 4 >}}**Case Studies and Literature Discussions; Case Study Project**{{< /td-colspan >}} ||||
| L12 | Case Study: Omeprazole Pharmacogenetics |  {{< br >}}{{< br >}} Chang, M., G. Tybring, et al. "[Interphenotype Differences in Disposition and Effect on Gastrin Levels of Omeprazole—Suitability of Omeprazole as a Probe for CYP2C19](http://dx.doi.org/10.1111/j.1365-2125.1995.tb04488.x)." _British Journal of Clinical Pharmacology_ 39, no. 5 (1995): 511–18. {{< br >}}{{< br >}} Furuta, Takahisa, Mitsushige Sugimoto, et al. "[CYP2C19 Pharmacogenomics Associated with Therapy of Helicobacter Pylori Infection and Gastro-Esophageal Reflux Diseases with a pPoton Pump Inhibitor](http://dx.doi.org/10.2217/14622416.8.9.1199)." _Pharmacogenomics_ 8, no. 9 (2007): 1199–210. {{< br >}}{{< br >}} Lindberg, Per, Peter Nordberg, et al. "[The Mechanism of Action of the Antisecretory Agent Omeprazole](http://dx.doi.org/10.1021/jm00158a001)." _Journal of Medicinal Chemistry_ 29, no. 8 (1986): 1327–29. {{< br >}}{{< br >}} Court, Michael H. "[A Pharmacogenomics Primer](http://dx.doi.org/10.1177/0091270007303768)." _The Journal of Clinical Pharmacology_ 47, no. 9 (2007): 1087–103. {{< br >}}{{< br >}} \[Golan\] Chapter 6 and 46 {{< br >}}{{< br >}}  |
| R5 | Overview of Drug Development 3 | \[Golan\] Chapter 49 |
| L13 | Case Study | No readings for this session. |
| L14 | Case Study: Antibiotics |  {{< br >}}{{< br >}} \[Golan\] Chapters 32, 33, and 34 {{< br >}}{{< br >}} [Antibiotic Resistance Threats in the United States, 2013](http://www.cdc.gov/drugresistance/threat-report-2013/) [(PDF - 4.0MB)]({{< baseurl >}}/resources/mit20_201f13_antbiorstnce) Centers for Disease Control and Prevention. {{< br >}}{{< br >}} Dwyer, Daniel J., Michael A. Kohanski, et al. "[Role of Reactive Oxygen Species in Antibiotic Action and Resistance](http://dx.doi.org/10.1016/j.mib.2009.06.018)." _Current Opinion in Microbiology_ 12, no. 5 (2009): 482–9. {{< br >}}{{< br >}}  |
| R6 | Project Help Session | No readings for this session. |
| L15 | Case Study | No readings for this session. |
| L16 | Dr. Alex Wood, MIT Senior Lecturer/Novartis: Case Study: Oncology Drugs | Hanahan, Douglas, and Robert A. Weinberg. "[Hallmarks of Cancer: The Next Generation](http://dx.doi.org/10.1016/j.cell.2011.02.013)." _Cell_ 144, no. 5 (2011): 646–74. |
| R7 | Project Help Session | No readings for this session. |
| L17 | Case Study: Statins |  {{< br >}}{{< br >}} \[Golan\] Chapter 19 {{< br >}}{{< br >}} Press Release: "[Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs](http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=1819)." October 29, 2004. {{< br >}}{{< br >}}  |
| R8 | Project Help Session | No readings for this session. |
| L18 | Case Study: GWAS and Statin Toxicity |  {{< br >}}{{< br >}} Niemi, M. "[Transporter Pharmacogenetics and Statin Toxicity](http://dx.doi.org/10.1038/clpt.2009.197)." _Clinical Pharmacology & Therapeutics_ 87, no. 1 (2010): 130–3. {{< br >}}{{< br >}} Link, E., S. Parish, et al. "[SLCO1B1 Variants and Statin-Induced Myopathy—A Genomewide Study](http://dx.doi.org/10.1056/NEJMoa0801936)." _The New England Journal of Medicine_ 359, no. 8 (2008): 789. {{< br >}}{{< br >}}  |
| L19 | Dr. Bernard Fermini, Pfizer: Case Study: Cardiotoxicity | No readings for this session. |
| R9 | Project Help Session | No readings for this session. |
| L20 | Dr. Teresa Wright, Shire Pharmaceuticals: Preclinical Drug Development | \[Golan\] Chapter 49 |
| R10 | Project Help Session | No readings for this session. |
| L21 | Dr. Keith Hoffmaster: Case Study: PK / PD | No readings for this session. |
| L22 | Case Study: Sarilumab Phase III Clinical Result |  {{< br >}}{{< br >}} Carroll, John. "[Regeneron, Sanofi Hit a Trio of Goals in First PhIII Test of Rheumatoid Arthritis Drug](http://www.fiercebiotech.com/story/regeneron-sanofi-hit-trio-goals-first-phiii-test-rheumatoid-arthritis-drug/2013-11-22)." _Fierce Biotech_, November 22, 2013. {{< br >}}{{< br >}} Huet, Natalie (rep.) and Elizabeth Piper (ed.). "[Sanofi, Regeneron Arthritis Drug Meets Goals in Phase 3 Trial](http://www.reuters.com/article/2013/11/22/us-sanofi-regeneron-clinicaltrial-idUSBRE9AL06S20131122)." _Reuters_, November 22, 2013. {{< br >}}{{< br >}} Bennett, Simeon. "[Sanofi Rheumatoid Arthritis Drug Cuts Pain, Damage in Study](http://www.bloomberg.com/news/2013-11-22/sanofi-rheumatoid-arthritis-drug-reduces-pain-damage-in-study.html)." _Bloomberg_, November 22, 2013. {{< br >}}{{< br >}}  |
| R11 | Prof. Doug Lauffenburger: Systems Pharmacology | No readings for this session. |
| L23 | Dr. Tess Schmalbach, Schmalbach LLC: The Clinical Size of Drug Development | \[Golan\] Chapters 50 and 51